Trial · NCT03463265
Results by group36
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 36
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| ORR | Arm A, Cohort 1: Nab-sirolimus in Patients With Recurrent High Grade Glioma | 0 | 95% Confidence Interval NA to NA | percentage of patients | |
| ORR | Arm A, Cohort 2: Nab-sirolimus + Temozolomide in Patients With Recurrent High Grade Glioma | 0 | 95% Confidence Interval NA to NA | percentage of patients | |
| ORR | Arm A, Cohort 3: Nab-sirolimus + Bevacizumab in Patients With Recurrent High Grade Glioma | 0 | 95% Confidence Interval NA to NA | percentage of patients | |
| ORR | Arm A, Cohort 4: Nab-sirolimus + Lomustine in Patients With Recurrent High Grade Glioma | 0 | 95% Confidence Interval NA to NA | percentage of patients | |
| ORR | Arm A, Cohort 5: Nab-sirolimus + Marizomib in Patients With Recurrent High Grade Glioma | 0 | 95% Confidence Interval NA to NA | percentage of patients | |
| ORR | Arm B: Nab-sirolimus + Temozolomide + Radiotherapy in Patients With Newly Diagnosed Glioblastoma | 11.5 | 95% Confidence Interval 2.4 to 30.2 | percentage of patients | |
| Median PFS | Arm A, Cohort 1: Nab-sirolimus in Patients With Recurrent High Grade Glioma | 1.7 | 95% Confidence Interval 1.3 to NA | months | |
| Median PFS | Arm A, Cohort 2: Nab-sirolimus + Temozolomide in Patients With Recurrent High Grade Glioma | 11.3 | 95% Confidence Interval 5.2 to NA | months | |
| Median PFS | Arm A, Cohort 3: Nab-sirolimus + Bevacizumab in Patients With Recurrent High Grade Glioma | 3.1 | 95% Confidence Interval 1.7 to 9.2 | months | |
| Median PFS | Arm A, Cohort 4: Nab-sirolimus + Lomustine in Patients With Recurrent High Grade Glioma | 3.8 | 95% Confidence Interval 1.4 to NA | months | |
| Median PFS | Arm A, Cohort 5: Nab-sirolimus + Marizomib in Patients With Recurrent High Grade Glioma | 1.7 | 95% Confidence Interval 0.9 to 3.5 | months | |
| Median PFS | Arm B: Nab-sirolimus + Temozolomide + Radiotherapy in Patients With Newly Diagnosed Glioblastoma | 7.5 | 95% Confidence Interval 6.2 to 14.4 | months | |
| PFS Rate at 6 Months and 12 Months | Arm A, Cohort 1: Nab-sirolimus in Patients With Recurrent High Grade Glioma | PFS at 6 months | 0.0 | 95% Confidence Interval NA to NA | percentage of patients |
| PFS Rate at 6 Months and 12 Months | Arm A, Cohort 2: Nab-sirolimus + Temozolomide in Patients With Recurrent High Grade Glioma | PFS at 6 months | 75.0 | 95% Confidence Interval 12.8 to 96.1 | percentage of patients |
| PFS Rate at 6 Months and 12 Months | Arm A, Cohort 3: Nab-sirolimus + Bevacizumab in Patients With Recurrent High Grade Glioma | PFS at 6 months | 37.5 | 95% Confidence Interval 8.7 to 67.4 | percentage of patients |
| PFS Rate at 6 Months and 12 Months | Arm A, Cohort 4: Nab-sirolimus + Lomustine in Patients With Recurrent High Grade Glioma | PFS at 6 months | 25.0 | 95% Confidence Interval 0.9 to 66.5 | percentage of patients |
| PFS Rate at 6 Months and 12 Months | Arm A, Cohort 5: Nab-sirolimus + Marizomib in Patients With Recurrent High Grade Glioma | PFS at 6 months | 10.0 | 95% Confidence Interval 0.6 to 35.8 | percentage of patients |
| PFS Rate at 6 Months and 12 Months | Arm B: Nab-sirolimus + Temozolomide + Radiotherapy in Patients With Newly Diagnosed Glioblastoma | PFS at 6 months | 76.9 | 95% Confidence Interval 55.7 to 88.9 | percentage of patients |
| PFS Rate at 6 Months and 12 Months | Arm A, Cohort 1: Nab-sirolimus in Patients With Recurrent High Grade Glioma | PFS at 12 months | 0.0 | 95% Confidence Interval NA to NA | percentage of patients |
| PFS Rate at 6 Months and 12 Months | Arm A, Cohort 2: Nab-sirolimus + Temozolomide in Patients With Recurrent High Grade Glioma | PFS at 12 months | 50.0 | 95% Confidence Interval 5.8 to 84.5 | percentage of patients |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03463265/results